Health & Biotech
Melbourne biotech Mesoblast (ASX:MSB) is attempting to commercialise a stem cell treatment known as remestemcel-L for conditions such as acute graft versus host disease, advanced heart failure and chronic lower back pain due to degenerative disc disease. Mesoblast acquired remestemcel-L from US-based Osiris Therapeutics in 2013.
Mesoblast’s proprietary process selects precursors and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell bank is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.
Mesoblast debuted on the ASX in 2004 and reached a peak valuation of $2.5 billion in 2011. The company dual listed on the Nasdaq in November 2015, accompanied by a $US63m capital raising.
The company was dealt a blow in October 2020 when the US Food and Drug Administration declined to approve remestemcel-L for the treatment of acute graft versus host disease in children, instead asking for more data. Mesoblast is expected to dispute the FDA’s decision.
Mesoblast licensed remestemcel-L to Swiss pharmaceutical giant Novartis in November 2020 for indications other than graft versus host disease, a devastating complication from bone marrow transplants.
RELATED STOCKHEAD STORIES
Health & Biotech
Mesoblast burnt $108m in FY20 waiting on key FDA ruling
Health & Biotech
Dr Boreham’s Crucible: Regeneus is now riding the stem cell rollercoaster upwards
Experts
Scopo’s powerplays: Investors love an ice queen
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
ASX Small Cap Lunch Wrap: Reality defying S&P 500 flirts with record high
Health & Biotech
Mesoblast caps off rollercoaster week with key tick of approval from US regulators
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Dr Boreham’s Crucible: Dimerix not putting all its eggs in one basket
Health & Biotech
How many stocks fighting COVID-19 have maintained their momentum?
Experts
Scopo’s health powerplays: The cash caboose keeps rolling on
News
Kick Back: The 10 biggest stories you might have missed on Stockhead this week
News
Bell Financial flags improved $23.5m H1 profit but shares dip
Health & Biotech
Dr Boreham’s Crucible: Mesoblast within months of 3 major trial results, key regulatory decision
Health & Biotech
COVID-19 adds $9bn to top four ASX health stocks
News
ASX rainmakers more than double their raisings in 2020 to $27bn
Experts
Scopo’s health powerplays: Clinical trials are back
Health & Biotech